Past, Present and Future: The Role of Central Laboratories in Alzheimer’s Disease Research

Life Sciences, Pharmaceutical,
  • Thursday, November 21, 2013

Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder that mainly affects the elderly population. The prevalence of AD is predicted to increase to 115.4 million by 2050(1). Despite having the first drug, Tacrine, approved by the FDA in 1993, there has been little progress made in the development of pharmacotherapy for AD treatment.

Currently there is no cure for AD, and treatments are symptomatic only. Even with the investment of more than a billion dollars by pharmaceutical companies, there have been no reliable disease-modifying therapies discovered that have received FDA approval(2). It is imperative to find better treatments for AD to alleviate patients’ and their families’ suffering, and to prevent a potential AD-associated global economic crisis.

Recently, major changes were made in the diagnostic criteria for AD and encompass the latest findings in the field, which is helping to facilitate more clinical research. Already, the usual clinical interview can be coupled with brain imaging testing approved by the FDA for the diagnosis of AD in live patients. Several disease-modifying or disease-preventing therapies are also appearing in clinical trials. Central laboratories can play a key role in clinical trials for AD drug development by assisting with patient population identification and by detecting, at an early stage, drugs that are likely to fail, leading to important time and costs savings.

This webinar will discuss the latest advances in AD research and explain how central laboratories can contribute to the progress in the battle against this disease by supporting clinical trials through quality testing.


(1) Alzheimer’s Disease International. World Alzheimer’s Report 2009: 25-46
(2) Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer’s disease: beyond cholinesterase inhibitors. Pharmacol. Ther. 2012;134(1): 8–25


Tatiana Souslova, M.Sc., Ph.D., Principal Scientist, ACM Global Central Laboratory

Dr. Tatiana Souslova holds a doctorate in neuroscience from the University of Ottawa, Canada and has 10 years of academic, industrial and diagnostic laboratory experience. At ACM Global Central Laboratory, Dr. Souslova oversees all clinical chemistry and research activities with an emphasis on providing high-quality, uniquely tailored solutions.

Message Presenter

Who Should Attend?

  • Scientific Affairs Directors
  • Medical Directors
  • Principal Scientists
  • PhDs
  • Laboratory Operations

Xtalks Partner

ACM Global Central Laboratory

ACM Global Central Laboratory specializes in delivering high-quality, central laboratory testing services designed to optimize clinical trial outcomes. Through a powerful combination of robust global capabilities, operational and scientific expertise and unsurpassed service, ACM Global acts as an extension of our clients’ clinical teams to develop and execute Smarter Testing strategies that deliver reliable outcomes for their clinical development programs. Operating in more than 60 countries, ACM Global’s analytical team performs more than 15 million diagnostic tests each year from a test menu with over 1,600 tests spanning all medical disciplines, including pathology, microbiology and molecular diagnostics, flow cytometry, specialized biomarkers, and pharmacogenomics.

For more information, visit, our Central Labs in Focus blog or call +1 866 405 0400.

Media Partner

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account